Which Patients with Advanced CSCC Will Likely Benefit Most from PD1 Checkpoint Inhibition?

Which Patients with Advanced CSCC Will Likely Benefit Most from PD1 Checkpoint Inhibition?


Published

November 28, 2018

Created by

CMEducation Resources symposium

Related Presenters

Karl Lewis, MD

Karl Lewis, MD

Associate Professor of MedicineDivision of Medical OncologyDirector, Cutaneous Oncology ProgramUniversity of Colorado School of Medicine